Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.41 |
| ▸ | BCR | P11274 | 6/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | KIT | P10721 | 6/20 | 0.39 |
| ▸ | ABL2 | P42684 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17153029 | 0.91 | JAK2 (0.51) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17152964 | 0.90 | KDR (0.47) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17152959 | 0.90 | STAT6 (0.43) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17153022 | 0.89 | JAK2 (0.52) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL18412513 | 0.89 | JAK2 (0.50) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17153243 | 0.89 | CDC7 (0.41) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17153061 | 0.85 | ABL1 (0.51) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17153219 | 0.85 | ACVR1 (0.39) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL17153019 | 0.84 | ACVR1 (0.39) | ABL1BCRPDGFRBSRCPDGFRA | |
| SCHEMBL18412516 | 0.84 | ACVR1 (0.39) | ABL1BCRPDGFRBSRCPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | ABL1 3037/4885BCR 4756/4885PDGFRB 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.